Trial Profile
A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms LCMC3 Trial
- Sponsors Genentech
- 25 Jan 2024 Status changed from active, no longer recruiting to completed.
- 07 Dec 2023 Results assessing pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer, published in the Journal of Thoracic Oncology.
- 19 Apr 2023 Results of exploratory analysis (n=53) assessing Efficacy and safety of adjuvant in patients with early stage non-small cell lung cancer atezolizumab presented at the 114th Annual Meeting of the American Association for Cancer Research